We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > rimegepant

News List

Pfizer and Biohaven close collaboration agreements pharmaceutical-business-review
January 06, 2022
pfizer has completed the collaboration transaction with Biohaven Pharmaceuticals to obtain rights to market the latter’s rimegepant and zavegepant outside of the US.
Biohaven Achieves Positive Results in Trial of Migraine Treatment americanpharmaceuticalreview
April 02, 2020
Biohaven Pharmaceutical announced positive topline results in its randomized, placebo-controlled pivotal clinical trial (NCT03732638) evaluating the efficacy and safety of oral rimegepant 75 mg.
The FDA drug decisions to watch in the first quarter of 2020 fiercepharma
January 06, 2020
It's a new year, which means it's a new opportunity for drugmakers hoping to pass FDA muster for new therapies––some of which could be sniffing after blockbuster sales.
New Migraine Drug, Rimegepant (Not Yet Approved) Might Help When Other Meds Don't drugs
July 11, 2019
A new migraine drug might offer an alternative to people who do not get relief from current medications, a new trial suggests.
Biohaven Enrolls First Patient in Rimegepant Phase 2 Clinical Trial americanpharmaceuticalreview
July 03, 2019
Biohaven announced that the first patient has been enrolled in a Phase 2 clinical trial assessing the efficacy and safety of rimegepant in treatment refractory trigeminal neuralgia.